Stock AnalizSabra Health Care REIT, Inc. SBRA
Real Estate Investment Trusts · data as of November 13, 2026
Sabra Health Care REIT, Inc. (SBRA) is a real estate company listed in the US with a market value of about $5.4B. In the twelve months to September 30, 2026 it had revenue of $919M and net income of $72M, a net margin of 7.8%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is shareholder returns (3/5); the weakest is value (0/5).
Key numbers: a P/E of 73.0, 5-year revenue growth of 5% a year. A discounted cash flow model with moderate assumptions puts its intrinsic value about 6% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- Profit margin improving
- Liabilities below 60% of assets
- Pays a dividend
- Dividend 3 years in a row
- Stock-based pay below 5% of revenue
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year revenue growth above 10% a year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $919M | $775M | $703M | $648M | $625M | $570M | $599M | $662M | $623M | $408M | $261M |
| Net income | $72M | $156M | $127M | $14M | -$78M | -$113M | $138M | $69M | $279M | $158M | $70M |
| Free cash flow | -$267M | -$104M | $174M | $222M | $224M | $257M | $262M | $321M | $99M | -$284M | $22M |
| EPS (diluted) | $0.28 | $0.64 | $0.54 | $0.06 | $-0.34 | $-0.52 | $0.67 | $0.37 | $1.51 | $1.40 | $0.92 |
| Net margin | 7.8% | 20.1% | 18.0% | 2.1% | -12.4% | -19.9% | 23.1% | 10.4% | 44.8% | 38.8% | 27.0% |
| ROIC | — | — | — | — | — | — | — | — | — | — | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 14 analysts is $22.64, 11% above the current price; targets range from $19.00 to $25.00; the consensus rating is “Buy”; expected EPS is $0.33 for the fiscal year ending December 31, 2026.
Frequently asked questions
What is Sabra Health Care REIT’s P/E ratio?
About 73.0, based on the last twelve months of diluted earnings per share (forward P/E about 30.9).
Is Sabra Health Care REIT stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 6% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Sabra Health Care REIT pay a dividend?
Yes. The dividend yield is about 5.72%, and it has paid dividends for 10 years in our data.
Is Sabra Health Care REIT a good stock to buy?
We do not give buy or sell advice. Sabra Health Care REIT scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.